Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 4Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Gastrointestinal 2Breast 2Thoracic 1Other hematologic neoplasm 1

Conditions

Leukemia 11Prostatic Neoplasms 9Breast Neoplasms 9Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neuroblastoma 6Myelodysplastic Syndromes 6Multiple Myeloma 6Melanoma 6Lymphoma 6Glioblastoma 6Ovarian Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Glioma 4Osteosarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms, Male 3Neoplasms, Plasma Cell 2Neoplasms 2Medulloblastoma 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Paclitaxel 95Carboplatin 81Bevacizumab 61Gemcitabine 36liposomal doxorubicin 31pembrolizumab 30Topotecan 26Taxes 23olaparib 22Immunoglobulin G 17Disulfides 17niraparib 16Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Marker Therapeutics, Inc.

Phase 2 Terminated
120 enrolled 12 charts
Gynecologic

Ovarian Neoplasms

NCT00088413 2019-04-16

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
51 enrolled 20 charts
BreastGastrointestinalGynecologic

Adenocarcinoma, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00157573 2017-05-08

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

Massachusetts General Hospital

Phase 2 Completed
72 enrolled 8 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00501644 2012-08-07

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
59 enrolled 5 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡